Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Atai BeckleyN. V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.
It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.
In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.
The company was formerly known as ATAI Life SciencesN. V. and changed its name to Atai BeckleyN. V. in November 2025.
Atai BeckleyN. V. was founded in 2018 and is headquartered in Amstelveen, The Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 18, 25 | -0.28 Decreased by -75.00% | -0.11 Decreased by -159.26% |
| Aug 14, 25 | -0.14 Increased by +61.11% | -0.12 Decreased by -16.67% |
| May 13, 25 | -0.15 Increased by +11.76% | -0.18 Increased by +16.67% |
| Mar 26, 25 | -0.24 Decreased by -100.00% | -0.15 Decreased by -60.00% |
| Nov 5, 24 | -0.16 Increased by +42.86% | -0.16 |
| Aug 6, 24 | -0.36 Decreased by -71.43% | -0.16 Decreased by -125.00% |
| May 15, 24 | -0.17 Increased by +19.05% | -0.18 Increased by +5.56% |
| Mar 28, 24 | -0.12 Increased by +57.14% | -0.16 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 749.00 K Increased by +1.77 K% | -61.07 M Decreased by -132.34% | Decreased by -8.15 K% Increased by +87.59% |
| Jun 30, 25 | 719.00 K Increased by +163.37% | -27.73 M Increased by +51.62% | Decreased by -3.86 K% Increased by +81.63% |
| Mar 31, 25 | 1.55 M Increased by +N/A% | -26.43 M Increased by +1.06% | Decreased by -1.70 K% Decreased by N/A% |
| Dec 31, 24 | -5.00 K Decreased by -127.78% | -38.96 M Decreased by -112.98% | Increased by +779.16 K% Increased by +866.72% |
| Sep 30, 24 | 40.00 K Decreased by -54.02% | -26.29 M Decreased by -159.41% | Decreased by -65.72 K% Decreased by -229.22% |
| Jun 30, 24 | 273.00 K Increased by +58.72% | -57.31 M Decreased by -73.45% | Decreased by -20.99 K% Decreased by -9.28% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -26.71 M Increased by +19.38% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 18.00 K Decreased by -52.63% | -18.29 M Increased by +59.36% | Decreased by -101.62 K% Increased by +14.21% |